AC607, mesenchymal stem cells for treatment of acute kidney injury

AC607 are expanded bone marrow-derived mesenchymal stem cells (MSC), obtained from healthy adult donors using a proprietary manufacturing process. For treatment of acute kidney injury (AKI), AC607 homes to the injured kidney, where it mediates anti-inflammatory and organ repair processes. AC607 avoids recognition by the immune system, enabling administration in an "off-the-shelf" paradigm without the need for tissue typing or immunosuppression.